Zhang Yifei, Li Xiaoying, Zou Dajin, Liu Wei, Yang Jialin, Zhu Na, Huo Li, Wang Miao, Hong Jie, Wu Peihong, Ren Guoguang, Ning Guang
Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrinology and Metabolism, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 RuiJin 2nd Road, Shanghai, People's Republic of China.
J Clin Endocrinol Metab. 2008 Jul;93(7):2559-65. doi: 10.1210/jc.2007-2404. Epub 2008 Apr 8.
Berberine, a natural plant alkaloid, is usually used as an antibiotic drug. The potential glucose-lowering effect of berberine was noted when it was used for diarrhea in diabetic patients. In vitro and in vivo studies have then showed its effects on hyperglycemia and dyslipidemia.
The objective of the study was to evaluate the efficacy and safety of berberine in the treatment of type 2 diabetic patients with dyslipidemia.
One hundred sixteen patients with type 2 diabetes and dyslipidemia were randomly allocated to receive berberine (1.0 g daily) and the placebo for 3 months. The primary outcomes were changes in plasma glucose and serum lipid concentrations. Glucose disposal rate (GDR) was measured using a hyperinsulinemic euglycemic clamp to assess insulin sensitivity.
In the berberine group, fasting and postload plasma glucose decreased from 7.0 +/- 0.8 to 5.6 +/- 0.9 and from 12.0 +/- 2.7 to 8.9 +/- 2.8 mm/liter, HbA1c from 7.5 +/- 1.0% to 6.6 +/- 0.7%, triglyceride from 2.51 +/- 2.04 to 1.61 +/- 1.10 mm/liter, total cholesterol from 5.31 +/- 0.98 to 4.35 +/- 0.96 mm/liter, and low-density lipoprotein-cholesterol from 3.23 +/- 0.81 to 2.55 +/- 0.77 mm/liter, with all parameters differing from placebo significantly (P < 0.0001, P < 0.0001, P < 0.0001, P = 0.001, P < 0.0001, and P <0.0001, respectively). The glucose disposal rate was increased after berberine treatment (P = 0.037), although no significant change was found between berberine and placebo groups (P = 0.063). Mild to moderate constipation was observed in five participants in the berberine group.
Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia.
黄连素是一种天然植物生物碱，通常用作抗生素药物。当它用于治疗糖尿病患者的腹泻时，其潜在的降血糖作用被注意到。随后的体外和体内研究表明了它对高血糖和血脂异常的作用。
本研究的目的是评估黄连素治疗2型糖尿病合并血脂异常患者的疗效和安全性。
116例2型糖尿病合并血脂异常患者被随机分配接受黄连素（每日1.0克）和安慰剂治疗3个月。主要结局是血浆葡萄糖和血清脂质浓度的变化。使用高胰岛素正常血糖钳夹技术测量葡萄糖处置率（GDR）以评估胰岛素敏感性。
黄连素组中，空腹和餐后血浆葡萄糖分别从7.0±0.8降至5.6±0.9以及从12.0±2.7降至8.9±2.8 mmol/L，糖化血红蛋白从7.5±1.0%降至6.6±0.7%，甘油三酯从2.51±2.04降至1.61±1.10 mmol/L，总胆固醇从5.31±0.98降至4.35±0.96 mmol/L，低密度脂蛋白胆固醇从3.23±0.81降至2.55±0.77 mmol/L，所有参数与安慰剂组相比均有显著差异（分别为P<0.0001、P<0.0001、P<0.0001、P = 0.001、P<0.0001和P<0.0001）。黄连素治疗后葡萄糖处置率增加（P = 0.037），尽管黄连素组与安慰剂组之间未发现显著变化（P = 0.063）。黄连素组有5名参与者出现轻度至中度便秘。
黄连素治疗2型糖尿病和血脂异常有效且安全。
